Mabion SA
WSE:MAB
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
10.2
22.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Mabion SA
Cash & Cash Equivalents
Mabion SA
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
M
|
Mabion SA
WSE:MAB
|
Cash & Cash Equivalents
zł47m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
R
|
Read Gene SA
WSE:RDG
|
Cash & Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
G
|
Genomed SA
WSE:GEN
|
Cash & Cash Equivalents
zł5.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
B
|
Bioton SA
WSE:BIO
|
Cash & Cash Equivalents
zł623k
|
CAGR 3-Years
-62%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-33%
|
|
U
|
Urteste SA
WSE:URT
|
Cash & Cash Equivalents
zł1.1m
|
CAGR 3-Years
39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
S
|
Synthaverse SA
WSE:SVE
|
Cash & Cash Equivalents
zł743k
|
CAGR 3-Years
-70%
|
CAGR 5-Years
30%
|
CAGR 10-Years
-23%
|
Mabion SA
Glance View
Mabion SA is a biotechnology company, which engages in the development and manufacture of biotech drugs. The company is headquartered in Konstantynow Lodzki, Woj. Lodzkie and currently employs 213 full-time employees. The company went IPO on 2010-08-10. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The firm specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. The company focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. The company operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
See Also
What is Mabion SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
47m
PLN
Based on the financial report for Sep 30, 2024, Mabion SA's Cash & Cash Equivalents amounts to 47m PLN.
What is Mabion SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
10%
Over the last year, the Cash & Cash Equivalents growth was -44%. The average annual Cash & Cash Equivalents growth rates for Mabion SA have been -18% over the past three years , 15% over the past five years , and 10% over the past ten years .